Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function

Oncogene

Volumn 33, Issue 39, 2014, Pages 4767-4777

  Beltran, A S ^a   Graves, L M ^a   Blancafort, P ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Dopaminergic neuron; Engrailed 1; Inflammatory breast cancer; Interference peptides; Reprogramming; Triple negative breast cancer

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BETA TUBULIN; CASPASE 3; CELL PENETRATING PEPTIDE; DOPAMINE TRANSPORTER; LENTIVIRUS VECTOR; PACLITAXEL; PROLINE TRANSFER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SHORT HAIRPIN RNA; SYNTHETIC INTERFERENCE PEPTIDE; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ENGRAILED 1; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; ANTINEOPLASTIC AGENT; EN1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; IPEP624; PEPTIDE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOPAMINERGIC NERVE CELL; GENE SILENCING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INFLAMMATORY BREAST CANCER; MOLECULAR MODEL; NUCLEAR REPROGRAMMING; OVERALL SURVIVAL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; RNA PROCESSING; TRANSCRIPTION REGULATION; BASAL CELL CARCINOMA; BREAST TUMOR; DRUG SCREENING; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; KAPLAN-MEIER ESTIMATE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, BASAL CELL; PEPTIDES;

EID: 84921797104     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.422     Document Type: Article

References (57)

1. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM et al. Genome and transcriptome sequencing in prospective refractory metastatic triple negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther 2012;2:104-116.
2. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011;13:R97.
3. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-399.
4. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumorinitiating features. Proc Natl Acad Sci USA 2009;106:13820-13825.
5. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010;15(Suppl 5):39-48.
6. Eiro N, Fernandez-Garcia B, Gonzalez LO, Vizoso FJ. Cytokines related to MMP-11 expression by inflammatory cells and breast cancer metastasis. Oncoimmunology 2013;2:e24010.
7. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol 2013.
8. Rachidi SM, Qin T, Sun S, Zheng WJ, Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS One 2013;8:e57911.
9. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003;5:31-36.
10. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013;339:286-291.
11. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA 2012;109:2802-2807.
12. Sasaki Y, Tsuda H. Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer 2009;16:254-259.
13. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
14. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-404.
15. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012;149:979-993.
16. Gray J, Druker B. Genomics: the breast cancer landscape. Nature 2012;486:328-329.
17. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:405-409.
18. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012;486:346-352.
19. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010;10:361-371.
20. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP et al. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res 2011;13:R94.
21. Alves Dos Santos MT, Smidt MP. En1 and Wnt signaling in midbrain dopaminergic neuronal development. Neural Dev 2011;6:23.
22. Alvarez-Fischer D, Fuchs J, Castagner F, Stettler O, Massiani-Beaudoin O, Moya KL et al. Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neuro 2011;14:1260-1266.
23. Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M et al. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int 2012;110:E287-E292.
24. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
25. Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genom 2011;4:3.
26. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
27. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ et al. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 2000;19:1052-1058.
28. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008;68:4674-4682.
29. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L Brca1 breast tumors contain distinct CD44 +/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
30. Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM et al. Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer 2008;7:29.
31. Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ et al. Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res 2007;13:2168-2177.
32. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527.
33. Nokes BT, Cunliffe HE, Lafleur B, Mount DW, Livingston RB, Futscher BW et al. In vitro assessment of the inflammatory breast cancer cell line SUM 149: discovery of 2 single nucleotide polymorphisms in the RNase L gene. J Cancer 2013;4:104-116.
34. Peltenburg LTC, Murre C. Engrailed and Hox homeodomain proteins contain a related Pbx interaction motif that recognizes a common structure present in Pbx. EMBO J 1996;15:3385-3393.
35. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell 2008;100:201-217.
36. Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol 2012;8:311-317.
37. Ninkovic J, Pinto L, Petricca S, Lepier A, Sun J, Rieger MA et al. The transcription factor Pax6 regulates survival of dopaminergic olfactory bulb neurons via crystallin alphaA. Neuron 2010;68:682-694.
38. Morini M, Astigiano S, Gitton Y, Emionite L, Mirisola V, Levi G et al. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC Cancer 2010;10:649.
39. Bell D, Bell A, Roberts D, Weber RS, El-Naggar AK. Developmental transcription factor EN1-a novel biomarker in human salivary gland adenoid cystic carcinoma. Cancer 2012;118:1288-1292.
40. Alberi L, Sgado P, Simon HH. Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development 2004;131:3229-3236.
41. Morrison BE, Marcondes MC, Nomura DK, Sanchez-Alavez M, Sanchez-Gonzalez A, Saar I et al. Cutting edge: IL-13Ralpha1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide. J Immunol 2012;189:5498-5502.
42. Kim J, Byun JW, Choi I, Kim B, Jeong HK, Jou I et al. PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Exp Neurobiol 2013;22:38-44.
43. Nolan YM, Sullivan AM, Toulouse A. Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol Med 2013;19:187-196.
44. Peltenburg LT, Murre C. Engrailed and Hox homeodomain proteins contain a related Pbx interaction motif that recognizes a common structure present in Pbx. EMBO J 1996;15:3385-3393.
45. Peltenburg LT, Murre C. Specific residues in the Pbx homeodomain differentially modulate the DNA-binding activity of Hox and Engrailed proteins. Development 1997;124:1089-1098.
46. La Ronde-Le Blanc NA, Wolberger C. Structure of HoxA9 and Pbx1 bound to DNA: Hox hexapeptide and DNA recognition anterior to posterior. Genes Dev 2003;17:2060-2072.
47. Morgan R, Pirard PM, Shears L, Sohal J, Pettengell R, Pandha HS. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res 2007;67:5806-5813.
48. Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer 2010;10:89.
49. Plowright L, Harrington KJ, Pandha HS, Morgan R. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer 2009;100:470-475.
50. Shears L, Plowright L, Harrington K, Pandha HS, Morgan R. Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol 2008;180:2196-2201.
51. Mukhopadhyay R, Jia J, Arif A, Ray PS, Fox PL. The GAIT system: a gatekeeper of inflammatory gene expression. Trends Biochem Sci 2009;34:324-331.
52. Arif A, Chatterjee P, Moodt RA, Fox PL. Heterotrimeric GAIT complex drives transcript-selective translation inhibition in murine macrophages. Mol Cell Biol 2012;32:5046-5055.
53. Yao P, Fox PL. A truncated tRNA synthetase directs a 'translational trickle' of gene expression. Cell Cycle 2012;11:1868-1869.
54. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 2010;11:718-719 author reply 711-720.
55. Beltran AS, Russo A, Lara H, Fan C, Lizardi PM, Blancafort P. Suppression of breast tumor growth and metastasis by an engineered transcription factor. PLoS One 2011;6:e24595.
56. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP et al. Generation of tumor initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res 2011;13:R94.
57. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 2006;7:96.